Maxim Group Sticks to Their Buy Rating for Soliton (SOLY)

By Austin Angelo

In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Soliton (SOLYResearch Report), with a price target of $25.00. The company’s shares closed last Friday at $12.88.

According to, Vendetti is a 5-star analyst with an average return of 19.2% and a 51.4% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Applied DNA Sciences, Milestone Scientific, and Sensus Healthcare.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Soliton with a $22.50 average price target.

See today’s analyst top recommended stocks >>

Based on Soliton’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $3.59 million. In comparison, last year the company had a GAAP net loss of $4.3 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Soliton, Inc. is a medical development company. It develops healthcare technological devices for medical and cosmetic treatments. The firm’s devices generate planar acoustic waves or shock waves in cosmetic surgical procedures, aesthetic surgical procedures, and dermatology procedures for treatments. The company was founded by Walter V. Klemp & Christopher Capelli and is headquartered in Houston, TX.